Results 261 to 270 of about 722,278 (319)

Onasemnogene Abeparvovec in Type I Spinal Muscular Atrophy: 24‐Month Follow‐Up From the Italian Registry

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Onasemnogene abeparvovec (OA) is an AAV9‐based gene therapy for spinal muscular atrophy type I (SMA I). Real‐world outcomes show increased response variability compared to clinical trials, and follow‐up data beyond 12–18 months are limited.
Marika Pane   +43 more
wiley   +1 more source

Threshold Signatures

open access: yesIEEE Security & Privacy
openaire   +1 more source

Identification of Pancreatic Ductal Adenocarcinoma Extracellular Matrix Signatures from In-Depth Proteomic Profiling that Correlate with Lymphocyte Infiltration. [PDF]

open access: yesCancer Res Commun
Considine JM   +8 more
europepmc   +1 more source

Mutational signature-based classification uncovers emerging oral cancer subtypes with distinct molecular patterns. [PDF]

open access: yesInt J Oral Sci
Deneuve S   +19 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy